» Articles » PMID: 32017078

Immunologic Impact of Chemoradiation in Cervical Cancer and How Immune Cell Infiltration Could Lead Toward Personalized Treatment

Overview
Journal Int J Cancer
Specialty Oncology
Date 2020 Feb 5
PMID 32017078
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the potential of tumor-infiltrating immune cells (ICs) as predictive or prognostic biomarkers for cervical cancer patients. In total, 38 patients treated with (chemo)radiotherapy and subsequent surgery were included in the current study. This unique treatment schedule makes it possible to analyze IC markers in pretreatment and posttreatment tissue specimens and their changes during treatment. IC markers for T cells (CD3, CD4, CD8 and FoxP3), macrophages (CD68 and CD163) and B cells (CD20), as well as IL33 and PD-L1, were retrospectively analyzed via immunohistochemistry. Patients were grouped in the low score or high score group based on the amount of positive cells on immunohistochemistry. Correlations to pathological complete response (pCR), cause-specific survival (CSS) and metastasis development during follow-up were evaluated. In analysis of pretreatment biopsies, significantly more pCR was seen for patients with CD8 = CD3, CD8 ≥ CD4, positive IL33 tumor cell (TC) scores, IL33 IC < TC and PD-L1 TC ≥5%. Besides patients with high CD8 scores, also patients with CD8 ≥ CD4, CD163 ≥ CD68 or PD-L1 IC ≥5% had better CSS. In the analysis of posttreatment specimens, less pCR was observed for patients with high CD8 or CD163 scores. Patients with decreasing CD8 or CD163 scores between pretreatment and posttreatment samples showed more pCR, whereas those with increasing CD8 or decreasing IL33 IC scores showed a worse CSS. Meanwhile, patients with an increasing CD3 score or stable/increasing PD-L1 IC score showed more metastasis during follow-up. In this way, the intratumoral IC landscape is a promising tool for prediction of outcome and response to (chemo)radiotherapy.

Citing Articles

Exploring MPC1 as a potential ferroptosis-linked biomarker in the cervical cancer tumor microenvironment: a comprehensive analysis.

Li M, Xu T, Yang R, Wang X, Zhang J, Wu S BMC Cancer. 2024; 24(1):1258.

PMID: 39390460 PMC: 11465577. DOI: 10.1186/s12885-024-12622-x.


Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.

Guan B, Xu M, Zheng R, Guan G, Xu B BMC Cancer. 2023; 23(1):1099.

PMID: 37953237 PMC: 10642053. DOI: 10.1186/s12885-023-11354-8.


The current understanding of the immune landscape relative to radiotherapy across tumor types.

Iliadi C, Verset L, Bouchart C, Martinive P, Van Gestel D, Krayem M Front Immunol. 2023; 14:1148692.

PMID: 37006319 PMC: 10060828. DOI: 10.3389/fimmu.2023.1148692.


Efficacy and optimal combination timing of chemotherapy combined with PD-1 inhibitor in advanced cervical cancer: a multicenter retrospective cohort study.

Ma Y, Cheng S, Zhang M, Zhang H, Gu J, Zhao P Ann Transl Med. 2022; 10(20):1107.

PMID: 36388810 PMC: 9652515. DOI: 10.21037/atm-22-4298.


Influence of chemoradiation on the immune microenvironment of cervical cancer patients.

Herter J, Kiljan M, Kunze S, Reinscheid M, Ibruli O, Cai J Strahlenther Onkol. 2022; 199(2):121-130.

PMID: 36251031 PMC: 9876875. DOI: 10.1007/s00066-022-02007-z.